secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0000950170-25-017075
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce
--------------------------------------------------------------------------------

- Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.
- Expects $1.1M severance charges; cash runway extended to second half of 2026.
- Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.
- Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/0000950170-25-017075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-017075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer